Prasugrel Could Avoid More Restrictive REMS Options, Lilly Hints
Executive Summary
Should a risk management and evaluation strategy accompany approval of Lilly's anti-platelet drug prasugrel, the product may escape the most burdensome REMS options, Lilly hinted during its July 24 earning call
You may also be interested in...
"Priority" Review Slow Down: The Prasugrel Delay
FDA is looking at a February advisory committee for the Lilly/Daiichi anti-clotting drug. That would put the review of the "priority" application at 14 months and counting. What does prasugrel mean for the priority review process?
Prasugrel Round Two: Is FDA Approval In Sight?
FDA action on Eli Lilly/Daiichi Sankyo’s clot buster anticipated Sept. 26.
Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)